Mangoceuticals, Inc. (MGRX) stock
Close on Nov 12, 2026Market cap $3.99MP/E –Yield –
Mangoceuticals, Inc. saw revenue fall 38.9% to $315.23K over the twelve months to Jun 30, 2026. At the latest close the market valued the company at $3.99M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $3.99M
- P/E ratio
- –
- Price to sales
- 12.66
- Price to book
- 0.32
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $315.23K
- Net income
- -$15.10M
- EPS, diluted
- -$1.22
- Book value per share
- $0.73
- Diluted shares
- 17M
Trading
- Previous close
- $0.20
- Open
- $0.19
- Day's range
- $0.18 – $0.20
- Volume
- 8,839,578
- Average volume (20 days)
- 792,239
- Beta (5 years)
- -1.22
- 52-week range
- $0.16 – $2.28
- RSI (14 days)
- 28.7
- Volatility (1 year)
- 213.0%
- Relative volume
- 0.96×
- WACC
- 7.4%
Market cap history
Month-end market cap since 2023, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | MGRX | S&P 500 | Difference | MGRX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -51.7% | -2.7% | −49.1 pts | ||
| 3 months | -65.3% | -1.7% | −63.5 pts | ||
| Year to date | -75.0% | +11.9% | −86.9 pts | ||
| 1 year | -89.5% | +12.0% | −101.5 pts | ||
| 3 years | -97.3% | +78.2% | −175.4 pts | -69.8% | +21.2% |
Five years at a glance
Fiscal years 2021 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Mangoceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- News
- Update
- Update
- Update
- Update
About Mangoceuticals
Services-Misc Health & Allied Services, NEC
Mangoceuticals, Inc. is a company that develops, markets, and sells men's health and wellness products and services, primarily focusing on telehealth and erectile dysfunction treatments. The company connects consumers with licensed healthcare professionals and partnered pharmacies to provide access to prescription and non-prescription wellness options. Its operations encompass several corporate subsidiaries and regional entities, including MangoRx Mexico and MangoRx UK Limited.
Company profile, executives and historyMangoceuticals stock: common questions
What is Mangoceuticals's stock price?
MGRX closed at $0.18 on Nov 12, 2026, down 7.18% on the day. Over the past 52 weeks it traded between $0.16 and $2.28.
What is Mangoceuticals's market cap?
Mangoceuticals was worth $3.99M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is MGRX's P/E ratio?
Mangoceuticals lost money over the twelve months to Jun 30, 2026 (diluted EPS -$1.22), so it has no meaningful P/E ratio.
How much revenue does Mangoceuticals make?
Mangoceuticals reported revenue of $315.23K for the twelve months to Jun 30, 2026, down 38.9% from a year earlier.
Does Mangoceuticals pay a dividend?
No. Mangoceuticals has not paid a cash dividend over the last twelve months.
How has MGRX stock performed over the past year?
Including dividends, MGRX returned -89.5% over the past year, against +12.0% for the S&P 500.
How many MGRX shares are sold short?
0M shares were sold short at the latest FINRA report, 0.59% of the float, or 1.0 days of average trading volume.
Who are Mangoceuticals's competitors?
Companies most similar to Mangoceuticals by business, industry and size include BRTX, BICX, MCTA, MWAI, NXL.
See a number that looks wrong?